- 1 Title: Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm
- 2 Development and Rupture: Insights from Genetic and Experimental Models
- 3
- 4 **Author:** Yaozhong Liu¹, Huilun Wang^{1,2}, Minzhi Yu³, Lei Cai⁴, Ying Zhao¹, Yalun
- 5 Cheng¹, Yongjie Deng¹, Yang Zhao¹, Haocheng Lu⁵, Xiaokang Wu¹, Guizhen Zhao^{1,6},
- 6 Chao Xue^{1,7}, Hongyu Liu¹, Ida Surakka¹, Anna Schwendeman³, Hong S. Lu⁴, Alan
- 7 Daugherty⁴, Lin Chang¹, Jifeng Zhang¹, Ryan E. Temel^{4,*}, Y. Eugene Chen^{1,8,*}, Yanhong
- 8 Guo^{1,*}
- 9
- ¹Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan
- 11 Medical Center, Ann Arbor, Michigan, USA.
- 12 ²Department of Molecular Physiology and Biological Physics, University of Virginia
- 13 School of Medicine, Charlottesville, Virginia, USA.
- ¹⁴ ³Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
- ⁴Saha Cardiovascular Research Center and Department of Physiology, College of
- 16 Medicine, University of Kentucky, Lexington, Kentucky 40536.
- ⁵Department of Pharmacology, Southern University of Science and Technology,
- 18 Guangdong, China.
- ⁶College of Pharmacy Health, University of Houston, Houston, Texas, USA.
- 20 ⁷Department of Internal Medicine, Rochester General Hospital, Rochester, New York,
- 21 USA.
- ⁸Center for Advanced Models for Translational Sciences and Therapeutics, University of
- 23 Michigan Medical Center, Ann Arbor, Michigan, USA.
- 24
- 25 Total word count: 8255
- 26

27 *** To whom correspondence should be addressed:**

- 28 Yanhong Guo, M.D., Ph.D., Department of Internal Medicine, University of Michigan
- 29 Medical Center, Ann Arbor, MI 48109, Phone: 734-764-1405, Email:
- 30 yanhongg@umich.edu
- 31 Or

- 32 Y. Eugene Chen, M.D., Ph.D., Department of Internal Medicine, University of Michigan
- 33 Medical Center, Ann Arbor, MI 48109, USA. Phone: 734-936-9548, Email:
- 34 echenum@umich.edu
- 35 Or
- 36 Ryan E. Temel, Ph.D., Saha Cardiovascular Research Center and Department of
- 37 Physiology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
- 38 Phone: 859-218-1706, Email: ryan.temel@uky.edu
- 39

40 Abstract:

- 41 Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective
- 42 medications. This study integrated genetic, proteomic, and metabolomic data to identify
- 43 causation between increased triglyceride (TG)-rich lipoproteins and AAA risk. Three
- 44 hypertriglyceridemia mouse models were employed to test the hypothesis that
- 45 increased plasma TG concentrations accelerate AAA development and rupture. In the
- 46 angiotensin II-infusion AAA model, most *LpI*-deficient mice with severely high plasma
- 47 TG concentrations died of aortic rupture. Consistently, *Apoa5*-deficient mice with
- 48 moderately increased TG concentrations had accelerated AAA development, while
- 49 human APOC3 transgenic mice with dramatically increased TG concentrations exhibited
- 50 aortic dissection and rupture. Increased TG concentrations and palmitate inhibited lysyl
- 51 oxidase maturation. Administration of antisense oligonucleotide targeting *Angptl3*
- 52 profoundly inhibited AAA progression in human *APOC3* transgenic mice and *Apoe*-
- 53 deficient mice. These results indicate that hypertriglyceridemia is a key contributor to
- 54 AAA pathogenesis, highlighting the importance of triglyceride-rich lipoprotein
- 55 management in treating AAA.

56

57

58 Introduction

59 Abdominal aortic aneurysm (AAA) is a progressive vascular disease characterized by 60 the localized enlargement of the abdominal aorta. The prevalence of AAA is estimated 61 to be as high as 8% in men and 2% in women over 65 years of age.¹ Most AAAs are 62 asymptomatic, but the mortality rate is up to 80% if rupture occurs.² As maximum aortic 63 diameter is the most established predictor of aneurysm rupture, current guidelines 64 recommend considering surgical repair for asymptomatic AAA patients when maximal aortic diameter is \geq 50 mm in women and \geq 55 mm in men. Open surgical or 65 66 percutaneous endovascular aneurysm repair is still the only therapeutic option.³ 67 Patients with AAA smaller than these thresholds are typically monitored through imaging surveillance. AAA-relevant risk factors, including smoking, male sex, aging, 68 hypertension, and hyperlipidemia, are associated with enhanced aneurysm formation 69 and growth. Currently, medications to reduce AAA risk factors, such as angiotensin II 70 71 (AngII) receptor antagonists, beta-adrenoceptor blockers, statins, and anticoagulants, 72 have not been proven effective in halting the growth of an aneurysm or preventing the 73 rupture of asymptomatic AAA based on the findings from randomized controlled trials.^{4,5} 74 75 Our recent comprehensive genome-wide association studies (GWAS) meta-analysis, 76 which included approximately 40,000 individuals with AAAs and over 1 million 77 individuals without AAAs, has demonstrated that one-third of the lead variants at the 78 121 genome-wide significant AAA risk loci are associated with major lipid fractions, such as total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), 79 or high-density lipoprotein cholesterol (HDL-C).⁶ Other genetic association studies have 80 81 identified that a 1-standard deviation increase in TG concentrations is associated with a 82 69% higher risk of AAA.^{7,8} Population-based studies have reported that individuals with increased serum very low-density lipoprotein-cholesterol (VLDL-C) and TG 83 84 concentrations are more likely to develop larger AAA sizes and have a higher risk of rupture.^{9,10} These epidemiologic and genetic findings suggest that increased TG-rich 85 lipoproteins (TRL) may accelerate AAA development and rupture, and modulating TG 86 87 concentrations or metabolites may become new therapeutic strategies for AAA. 88 89 TG, also known as triacylglycerols (TAG), are composed of glycerol and fatty acids and are the most abundant lipids in the body. Chylomicrons transport dietary triglycerides 90 91 from the small intestines, and VLDLs transport endogenously synthesized triglycerides 92 from the liver to peripheral tissues, such as the heart, skeletal muscle, and adipose tissues. Triglyceride metabolism is a complex process involving the breakdown and 93 94 utilization of this lipid. Several proteins and enzymes play critical roles in regulating

95 triglyceride metabolism.¹¹ Among these, lipoprotein lipase (LPL), ApoC-III

- 96 (apolipoprotein C-III, APOC3), ApoC-II, ApoA-V (apolipoprotein A5, APOA5), and
- 97 angiopoietin-like proteins (ANGPTL3, ANGPTL4, and ANGPTL8) are key players. LPL is
- 98 a critical enzyme that facilitates the hydrolysis of triglycerides carried by chylomicrons
- and VLDL into free fatty acids (FFA) and glycerol, allowing them to be utilized by various
- 100 cells for energy or storage. Our previous study found that an intronic LPL variant,
- 101 associated with increased LPL expression, was strongly related to reduced plasma TG
- 102 concentrations and AAA risk.⁶ APOA5 is almost exclusively expressed in the liver and
- 103 secreted in conjunction with VLDL particles. ApoC-III is a constituent of chylomicrons
- and VLDL particles and inhibits LPL activity, while ApoA-V and ApoC-II enhance LPL
- activity and promote the clearance of TG-rich lipoproteins. ANGPTL3 and ANGPTL8 are
- 106 secreted proteins and inhibitors of LPL-mediated plasma TG clearance. In numerous
- 107 studies involving humans and animals, loss-of-function of APOC2 or APOA5 is
- 108 associated with increased plasma concentrations of TG and chylomicronemia.^{12,13}
- 109 Among the putatively causal circulating proteins associated with AAA, we observed that
- 110 higher APOA5 expression is associated with decreased AAA risk.⁶ Conversely, gene
- silencing of APOC3 or ANGPTL3 significantly reduced TG and TC concentrations,
- 112 making this method an effective strategy for lowering plasma lipids and preventing
- 113 cardiovascular diseases.¹⁴⁻¹⁷ In the present study, we demonstrated that increased TG-
- rich lipoproteins accelerate AAA formation and rupture, and we provide evidence that
- 115 effective management of plasma TG concentrations can alleviate AAA progression.
- 116

117 Methods

- A detailed description of the methods is available in the Supplemental Materials. All
- animal procedures followed the protocols approved by the Institutional Animal Care &
- 120 Use Committee (IACUC) at the University of Michigan and University of Kentucky.
- 121

122 Statistic analysis

- 123 Analyses of RNA sequencing and genetic data were performed using R language
- 124 (v4.3.0). Statistical analyses of other data were conducted using GraphPad Prism 10.
- 125 Most of the data are presented as mean ± standard error of the mean (SEM). The
- 126 distribution of data was assessed using the Kolmogorov-Smirnov test (for n > 4) or the
- 127 Shapiro-Wilk test (for $n \le 4$). For normally distributed data, Student's t-tests were used
- to compare two groups, one-way analysis of variance (ANOVA) was used to compare
- 129 multiple groups, and the Sidak method was applied for multiple comparison correction.
- 130 For non-normally distributed data, Mann-Whitney U tests were used to compare two
- 131 groups, Kruskal-Wallis tests were employed to compare multiple groups, and the Dunn
- 132 method was used for multiple comparisons correction. A P-value less than 0.05 was
- 133 considered statistically significant.

134 Results

Genetic, proteomic, and metabolic studies underscore high triglyceride-rich lipoproteins as a causal risk factor for AAA.

137 Genetic variants that modulate the expression of genes encoding the candidate proteins 138 or the abundances of metabolites represent valuable tools for guiding therapeutic 139 strategies. Recent studies have identified cis-acting protein quantitative trait loci (cispQTL) that can be used as instrumental variables (IVs) for inferring causality.^{18,19} 140 141 Combining cis-pQTL and GWAS findings, we performed Mendelian randomization (MR) 142 analyses to assess the causal effects of circulating proteins on AAA risk and identified 143 that 41 out of 2,698 circulating proteins were significantly associated with AAA after 144 adjusting for multiple tests (Fig 1, full MR results in Supplementary Table 1). Among 145 them, genetically determined circulating APOC3 (OR=1.84) and APOA5 (OR=0.61) had 146 the most significant effects on AAA risk. Seven of the 41 circulating proteins, including 147 APOC3, APOA5, LPL, APOE, PLTP (phospholipid transfer protein), PCSK9 (proprotein) 148 convertase subtilisin/kexin type 9), and LPA (lipoprotein(A)), play an important role in 149 lipid metabolism, especially in VLDL and chylomicron metabolism (Fig 1B). Our previous 150 GWAS findings demonstrated that 42 lead variants at the AAA risk loci are associated with major lipid fractions.⁶ After prioritizing the role of five major lipoprotein components 151 152 (HDL-C, LDL-C, TG, APOA1, and APOB) as risk factors for AAA, TG was the top-ranked 153 risk factor for AAA with a marginal inclusion probability of 0.81 (P=0.007; Supplementary Table 2). Consistent with previous studies,⁶⁻⁸ LDL-C, HDL-C, and APOA1 were 154 significant factors (Supplementary Table 2). These genetic and proteomic findings 155

- 156 indicate that TG-related metabolism may play a substantial role in AAA pathogenesis.
- 157

158 To further identify genetic associations between AAA risk loci and circulating metabolic

traits, we utilized the data from a recently published GWAS study of 233 circulating

160 metabolites to perform a two-sample MR analysis.²⁰ The NMR-measured metabolites

161 included 213 lipid traits (lipids, lipoproteins, and fatty acids) and 20 non-lipid traits

162 (amino acids, ketone bodies, and glucose/glycolysis-related metabolites).²⁰ Lipoproteins

are classified by particle sizes (XXL, XL, L, M, S, and XS) and then subgrouped by the

164 components (particle number, phospholipids, cholesterol, cholesterol ester, free

165 cholesterol, and TG). For each metabolite, we used the inverse variance-weighted

166 (IVW) method as the primary MR approach and MR-Egger analysis and weighted

167 median-based regression methods as sensitivity analyses. We demonstrated that TG-

rich lipoproteins, including VLDL, IDL (intermediate density lipoprotein), and LDL, and all

the components in TRL particles, were positively associated with AAA risk, while HDL

and glucose were negatively associated with AAA risk, consistent with population

171 findings (Fig 1C, full MR results in Supplementary Table 3).^{9,10,21,22} Interestingly, we

- 172 noticed that TG component of HDL was positively associated with AAA risk compared to
- 173 other components in HDL particles, such as cholesterol and phospholipids (Fig 1C).
- 174 Concomitantly, we observed that total fatty acid and saturated fatty acid, the metabolites
- of triglycerides, were also positively associated with AAA risk. These findings raise the
- 176 possibility that lowering triglycerides and related metabolites could provide a therapeutic
- 177 pathway for reducing the risk of AAA.
- 178

179 Impaired LPL activity accelerates AAA development and rupture.

- 180 Chronic subcutaneous infusion of AnglI serves as a well-established AAA model in mice
- 181 under hypercholesterolemic conditions, which includes using mice with deficiencies in
- apolipoprotein E (*Apoe*) or LDL receptor (*Ldlr*) or manipulating by adeno-associated
- 183 virus-mediated overexpression of *Pcsk9* to induce hyperlipidemia.²³⁻²⁵ Our previous
- 184 GWAS demonstrated that LPL variants that lead to increased plasma TG concentrations
- 185 were linked to an increased risk of AAA.⁶ The MR analysis also identified circulating LPL
- 186 levels to be negatively associated with AAA risk (Fig 1B). To validate whether increased
- 187 TG concentrations caused by impaired LPL activity can result in AAA development and
- rupture, we infused AngII into male, inducible *LpI*-deficient ($iLpI^{-}$) mice fed a low-
- cholesterol Western diet. With Angll infusion, an aortic rupture occurred in 94% (16/17,
- 190 combined data from two cohorts of animal studies) of $iLpL^{-}$ mice compared to 9.5%
- 191 (2/21, combined data from two cohorts of animal studies) aortic rupture rate in littermate
- 192 control mice (Fig 2A-C, Supplementary Fig 1). The only survival i*Lpt^{-/-}* mouse did not
- 193 have AAA and had a plasma TG concentration of 474 mg/dL and TC concentration of
- 194 233 mg/dL. In contrast, after 1 week of Western diet feeding but before AngII infusion,
- the majority of the $iLpl^{-}$ mice had severely increased TG concentrations, which were as
- high as 11,103 mg/dL (4,077 ± 3,218 mg/dL) compared to 66 ± 28 mg/dL in $Lp^{f/f}$ mice
- 197 (Supplementary Fig 1A). Saline infusion, as a control, did not cause aortic rupture in
- either genotype (Supplementary Fig 1C). These findings showed that severely
- increased TG concentrations as a consequence of LPL deficiency resulted in aortic
- 200 rupture and death in the AnglI-induced AAA model.
- 201
- Then, we employed other mouse strains with increased, but not severely elevated, TG
- 203 concentrations to validate our hypothesis. We performed all the following AAA studies in
- 204 mice fed a standard rodent laboratory diet to minimize the effects of
- 205 hypercholesterolemia induced by a Western diet. ApoA-V is produced in the liver and
- 206 secreted into circulation, where it exerts an important role in regulating plasma TG
- 207 concentrations by enhancing LPL activity to hydrolyze triglycerides. Male Apoa5-
- 208 deficient mice showed a 2-3-fold increase in TG concentrations but no difference in TC
- 209 concentrations (Fig 2D-G), consistent with previous findings.¹² AAA was evaluated after
- a 4-week AnglI infusion. The hypertriglyceridemic *Apoa5*-deficient mice had increased

- AAA incidence and larger maximal abdominal aorta diameter (Fig 2E, H, I). There was
- no difference in blood pressure before and after Angll infusion between *Apoa5*-deficient
- 213 mice and their littermate controls (Fig 2J). This phenotype was not observed in *Apoa5*-
- 214 deficient female mice, which had only slightly increased TG concentrations (Fig 2K-O).
- In addition, female mice demonstrate markedly lower incidences of AAA than males due
- to sex hormones or sex chromosomes.²⁶ These findings imply the causative roles of
- 217 elevated TG concentrations in AAA pathogenesis.
- 218

Moderately to severely increased triglyceride levels accelerate AAA development and rupture in human *APOC3* transgenic mice.

- 221 Increased plasma ApoC-III concentrations are linked to enhanced production and
- slowed clearance of triglyceride-rich lipoproteins, causing hypertriglyceridemia. Human
- 223 APOC3 transgenic (hAPOC3 Tg) mice and age/sex-matched wild-type littermates were
- fed a standard rodent laboratory diet (Fig 3A). Compared with controls, male hAPOC3
- Tg mice had about 7-fold increase in plasma TG concentrations (Fig 3B) and about 1-
- fold elevations in plasma TC concentrations (Fig 3C) and non-esterified fatty acids
- (NEFA, Fig 3D). We observed a low incidence of AAA in wild-type littermates (2 out of
- 17), similar to the literature.²⁶ However, there was a dramatically increased AAA
- incidence and a larger maximal diameter of the suprarenal aorta in hAPOC3 Tg mice
- 230 (11 out of 13 surviving animals), as well as a higher dissection rate (8 out of 13 surviving
- animals) and another 2 mice dying from AAA rupture (Fig 3E-H). There was no
- 232 difference in systolic blood pressure (SBP) between hAPOC3 Tg mice and controls (Fig
- 31). A similar phenotype was observed in female mice (Fig 3J-O), indicating that
- dramatically increased TG concentrations accelerated AAA development, surpassing
- the protective effects of female hormones.
- 236

237 The effects of increased TG concentrations on AAA development were also evaluated in

- a PPE (porcine pancreatic elastase)-induced AAA model, in which AAA progression is
- independent of hypercholesterolemia.²⁷ Based upon a 50% increase in the maximal
- abdominal aorta diameter as AAA on day 14 post-operative, the incidence of AAA was
- 100% for both male and female hAPOC3 Tg and littermate control mice (Supplementary
- Fig 2 and Supplementary Fig 3). Male hAPOC3 Tg mice showed significantly larger
- 243 maximal aortic diameters than littermate controls, demonstrating that increased TG
- concentrations accelerated AAA growth (Supplementary Fig 2A-E). Even though female
- hAPOC3 Tg mice had lower TG concentrations than males (635 ± 36 mg/dL v.s. 946 ±
- 246 258 mg/dL, p = 0.0005), the increased TG concentrations in females were sufficient to
- cause larger aortic diameters (Supplementary Fig 3A-D).
- 248

These findings from the three hyperglyceridemia mouse models indicate that increased

- TG concentrations accelerate AAA rupture and aneurysm growth.
- 251

252 Palmitate and increased triglyceride concentrations inhibit lysyl oxidase

253 maturation in human aortic smooth muscle cells and aortas.

The pathophysiology of AAA is intricately linked to the disruption of smooth muscle cell

- 255 (SMC) homeostasis within the aortic wall, including phenotypic switching, cell death,
- extracellular matrix (ECM) remodeling, and inflammatory responses.²⁸ Serum from
- 257 *Apoa5*-deficient or h*APOC3* Tg mice, as well as VLDL and HDL particles, did not affect
- 258 primary human aortic smooth muscle cell (HASMC) viability (Supplementary Fig 4A-C),
- while incubation with LDL slightly increased cell numbers (Supplementary Fig 4C). The
- 260 presence of APOA5 in the conditional medium did not regulate the expression of
- 261 contractile markers in the presence of either Platelet-Derived Growth Factor-BB (PDGF-
- BB) or Transforming growth factor-beta (TGF β) (data not shown), suggesting other
- 263 mechanisms may exist. APOC3 overexpression caused elevated plasma TG
- 264 concentrations accompanied by increased plasma NEFA concentrations (Fig 3D and
- Supplementary Fig 2C). Palmitic acid (PA) is the most common saturated fatty acid in
- the human body, typically accounting for 20–30% of the total fatty acids.²⁹ Bulk RNA
- sequencing (RNA-seq) analysis was performed to compare PA-incubated HASMC with
- BSA-treated (vehicle control) cells. Compared to the BSA-incubated group, PA-
- 269 incubated HASMC showed an apparent reduction in ECM assembly pathways,
- 270 including collagen chain trimerization, elastic fiber formation and maturation, (Fig 4A-D),
- and increased expression of the inflammation-related gene (Supplementary Fig 5A-B,
- 272 Supplementary Table 4).
- 273
- TGF- β and lysyl oxidase (LOX) are crucial in regulating the cross-linking of collagen and
- elastin in the ECM. LOX was unexpectedly upregulated compared to the most
- downregulated genes in the elastic fiber formation and maturation pathways (Fig 4D). In
- 277 primary HASMC, PA incubation induced the transcription of LOX, showing increased
- 278 mRNA abundance by qRT-PCR (Fig 4E). LOX is initially synthesized as a preproprotein,
- which undergoes several post-translational modifications for its maturation and
- functional activation. Impairments in LOX activity, whether due to genetic mutations or
- LOX inhibitors, can lead to AAA formation and rupture.³⁰⁻³² Our RNA-seq data indicated
- that PA incubation downregulated the expression of BMP-1 (Bone morphogenetic
- protein 1), ADAMTS2 (a disintegrin and metalloproteinase with thrombospondin motif 2),
- and ADAMTS14, which are critical enzymes controlling LOX activation by the proteolytic
- removal of the propeptide region. We further confirmed that PA incubation
- downregulated BMP-1 and ADAMTS2 transcriptions in HASMCs (Fig 4F). Immunoblot
- analyses demonstrated that incubation with TGF- β increased the abundance of the

- 288 mature form of LOX. However, the presence of PA blocked its effect, resulting in a less
- 289 mature LOX (Fig 4G, I). LOX overexpression increased the mature form of LOX in
- HASMC, which was suppressed by incubation with PA (Fig 4H), indicating that PA
- 291 interferes with the maturation process of LOX in HASMC. Nicotine, one of the well-
- 292 established AAA risk factors, also repressed LOX maturation in HASMC
- 293 (Supplementary Fig 6). These findings suggest that PA and nicotine may play a
- 294 synergistic role in the pathogenesis of AAA by blocking LOX activation.
- 295
- 296 To investigate the effects of increased circulating palmitate concentrations on the
- 297 maturation of LOX in aortas, we administered ethyl palmitate, which can be hydrolyzed
- to free palmitate in rodents.³³ The mature LOX abundance in suprarenal abdominal
- aortas was inhibited significantly after administration of ethyl palmitate compared to the
- 300 vehicle or control intact aortas (Fig 4J). Then, we examined whether increased TG
- 301 concentrations affected the maturation of LOX in the aortas of hAPOC3 Tg and
- 302 littermate control mice. There was no difference in the abundance of matured LOX in
- 303 suprarenal abdominal aortas between the two groups without AngII infusion (Fig 4K).
- 304 We observed a dramatic upregulation of mature LOX upon AnglI infusion in control mice
- 305 (Fig 4K), suggesting a protective and compensatory mechanism to enhance elastic fiber
- 306 assembly to protect against the effects of AngII. However, this response disappeared in
- hAPOC3 Tg mice (Fig 4K), indicating that increased TG and/or palmitate inhibited LOX
 maturation in the aortas, which may contribute to AAA development and rupture.
- 309

310 Angpt/3 ASO inhibits AAA formation and rupture in APOC3 Tg mice.

- 311 Based on the above findings, we asked whether lowering TG levels could attenuate
- 312 AAA formation and rupture. We administrated fenofibrate and niacin, commonly used for
- treating hypertriglyceridemia, but only observed a 14-17 % reduction of plasma TG
- 314 concentrations in hAPOC3 Tg mice (Supplementary Fig 7). N-acetylgalactosamine
- 315 (GalNAc)-conjugated antisense nucleotides (ASO) targeting of hepatocyte ANGPTL3
- results in significantly decreased plasma TG concentrations in animals and
- 317 humans.^{15,16,34} In hAPOC3 Tg mice, administration of Angpt/3 ASO dramatically
- suppressed hepatic *Angpt/3* mRNA abundance by 64% and the plasma ANGPTL3
- 319 concentrations by 81% (Fig 5A-C). Consequently, administration of the Angpt/3 ASO
- 320 significantly reduced concentrations of NEFA, triglycerides (from $1,119 \pm 98 \text{ mg/dL}$ to
- 321 586 \pm 114 mg/dL) and total cholesterol (from 283 \pm 103 mg/dL to 117 \pm 58 mg/dL) (Fig
- 322 5D-F). Consistent with the above findings, increased TG concentrations in hAPOC3 Tg
- 323 mice accelerated AAA development during AnglI infusion (Fig 5G-L). After
- 324 administration of Angpt/3 ASO to hAPOC3 Tg mice, we recorded significant reductions
- in AAA incidence, maximal aortic diameter, elastin degradation, and dissection,
- 326 comparable to the control mice (Fig 5G-L). qRT-PCR and ELISA analysis showed no

- 327 significant changes in the levels of mouse *Apoc3* and human *APOC3* (Fig 5M-P). There
- 328 were no significant changes in the TG and TC metabolism-related genes in the liver,
- such as Apoc2, Apoa5, Apoe, Apob, Mttp, Fasn, Srebp1c, Ldlr, and Pcsk9
- 330 (Supplementary Fig 8). Angpt/3 ASO administration did not significantly change body
- 331 weight or systolic blood pressure (Fig 5Q-R). Overall, our findings demonstrate that
- administration of *Angptl3* ASO protected against hypertriglyceridemia accelerated AAA
- development in h*APOC3* Tg mice.
- 334

335 Angpt/3 ASO inhibits AAA development in Apoe-deficient mice.

- 336 ApoE-deficient mice have high levels of VLDL due to impaired clearance of chylomicron
- and VLDL. Compared with age and sex-matched C57BL/6J mice, *Apoe*-deficient mice
- 338 show significantly increased plasma levels of TC and moderately increased TG levels
- when fed a standard rodent diet.³⁵ Similar to the observation in hAPOC3 Tg mice,
- administration of *Angptl3* ASO dramatically reduced hepatic *Angptl3* mRNA expression
- and the circulating levels of ANGPTL3 (Fig 6A-C). As expected, administration of the
- 342 *AngptI3* ASO significantly decreased TG concentrations by 50%, NEFA by 31%, and
- 343 slightly decreased TC concentrations by 8% in *Apoe*-deficient mice fed a standard
- rodent laboratory diet (Fig 6D-F). We also used size exclusion chromatography to
- 345 separate lipoprotein classes and found decreased TG concentrations, mainly in VLDL
- and IDL (Fig 6I), while cholesterol concentrations were slightly reduced in VLDL and
 HDL (Fig 6J). Blood pressure measurements and body weight recordings revealed no
- 348 significant difference between control ASO and *Angpt/3* ASO-administered mice (Fig
- 6G, H). Consistent with the literature, AAA incidence in *Appe*-deficient mice was 83% in
- 350 the control group (Fig 6K, N). *Angpt/3* ASO administration largely inhibited AAA
- 351 development, as evidenced by significantly decreased AAA incidence and maximal
- aortic diameters (Fig 6N, O). Depletion of hepatic *Angpt/3* had limited effects on the
- expression of genes involved in lipogenesis and cholesterol metabolism (Fig 6P). Taken
- together, these data demonstrated that lowering TG and NEFA concentrations by
- 355 *Angpt/3* ASO inhibited AAA development in *Apoe*-deficient mice.
- 356

357 **Discussion**

- AAA screening programs have identified many asymptomatic AAA and effectively reduced aneurysm-related mortality. Thus, limiting aneurysm growth and reducing the
- 360 risk of aneurysm rupture has become a key priority for the treatment of AAA.³⁶ Based on
- 361 the genetic, proteomic, and metabolomic findings, we identify that increased TG
- 362 concentrations accelerate AAA formation and rupture using three hypertriglyceridemia
- 363 murine models. Of clinical relevance, we provide evidence that lowering TG and NEFA

364 concentrations by *Angptl3* ASO administration dramatically inhibited AAA development365 and rupture.

366

367 Mendelian Randomization (MR) using protein quantitative trait loci (pQTLs) as 368 instrumental variables (IVs) can help infer causality and identify drug targets for 369 complex diseases. By integrating pQTLs from ten large GWAS on circulating proteins, 370 we updated the 'actionable' druggable target pool into an enlarged set of 2,698 proteins. 371 Genetically determined APOA5 and LPL, two critical molecules regulating triglyceride 372 metabolism, were negatively associated with AAA risk. In contrast, the variants related 373 to APOC3 with increased TG concentrations were associated with increased AAA risk, 374 underscoring the role of triglyceride metabolism in human AAA development, consistent 375 with other genetic findings.^{7,8} We further explored the causal effects of metabolites on 376 AAA risk using IVs from 233 NMR-measured circulating metabolites.²⁰ The strong associations found in VLDL and its subfractions as well as free fatty acid concentrations, 377 378 further highlighted the importance of TG metabolism in AAA. Collectively, these findings 379 emphasize the significance of TG in AAA risk and provide potential candidates for AAA 380 prevention and treatment.

381

382 According to the literature and our experience, young C57BL/6J mice, when fed a 383 standard rodent laboratory diet, have low AAA incidence when infused with Angll.^{26,37} 384 Hyperlipidemia increases the AAA incidence during AnglI infusion in Ldlr and Apoe-385 deficient mice or C57BL/6J mice with an AAV expressing a gain-of-function mutant of PCSK9, in which Ldlr-deficient mice and PCSK9 overexpressing mice are fed a Western 386 diet to augment hypercholesterolemia.²⁶ Compared with C57BL/6J mice, Ldlr or Apoe-387 388 deficient mice have significantly increased TC and TG concentrations, which mainly 389 distribute in VLDL fractions using size exclusion chromatography to separate lipoprotein classes,³⁸ indicating that increased concentrations of large, TG-rich lipoproteins are 390 391 associated with AAA formation. Our previous study demonstrated that AAA development 392 is accelerated with modestly hypercholesterolemic conditions, but further elevation of 393 cholesterol above a threshold level does not enhance AAA progression.³⁷ Here, we 394 present that increased TG concentrations contribute to AAA development, dissection, 395 and rupture in a TG-concentration-dependent manner using three hypertriglyceridemia 396 mouse models. The moderately increased TG concentrations in Apoa5 deficiency mice 397 accelerated AAA development, dramatically increased TG concentrations in hAPOC3 398 transgenic mice caused AAA dissection, and severely high TG concentrations resulted 399 in a ortic rupture and death in inducible *Lpl*-deficient mice. We also evaluated the effects 400 of increased TG concentrations on aneurysm growth in the elastase-induced AAA 401 model. Previous studies have demonstrated that the aneurysm growth in the PPE 402 model is independent of hypercholesterolemic conditions using C57BL/6J mice with

403 PCSK9 overexpression or *Apoe*-deficient mice.^{27,39} Using the PPE-induced AAA model,

- 404 we demonstrated that increased TG concentrations aggravated AAA growth in both
- 405 male and female *APOC3* Tg mice. Furthermore, clinical observation shows that plasma
- 406 TG concentrations are higher in AAA patients than in controls.⁹ In a prospective
- 407 epidemiological study (the British United Provident Association [BUPA] study), the risk of
- 408 death from AAA rupture is strongly related to serum TG concentrations.¹⁰ Together,
- these findings pave the way for future studies of the role of triglyceride and related
- 410 metabolites in AAA development.
- 411
- Importantly, our study demonstrates that lowering TG and NEFA levels by administrating
- 413 Angpt/3 ASO inhibits AAA development in both hAPOC3 transgenic mice and Apoe-
- 414 deficient mice. ApoC-III raises TG concentrations by inhibiting LPL activity, reducing
- 415 hepatic uptake of TG-rich lipoproteins, and promoting VLDL secretion. ApoE acts as a
- 416 critical ligand for the LDL receptor and the LDL receptor-related protein, facilitating the
- 417 uptake of chylomicron and VLDL remnants into hepatocytes. Deficiency of ApoE causes
- 418 elevated TG and TC levels. In both APOC3 transgenic mice and Apoe-deficient mice,
- 419 triglycerides and cholesterol are mainly distributed in VLDL fractions. Administration of
- 420 Angpt/3 ASO dramatically reduced TG levels in VLDL and IDL fractions, consistent with
- 421 decreased TG concentrations in plasma, supporting the hypothesis that large-sized TG-
- rich lipoproteins and related metabolites contribute to AAA progression and rupture.
- These findings also provide evidence that lowering TG-rich lipoproteins is a potential
- therapeutic strategy. ANGPTL8 and ANGPTL3 form a complex that markedly inhibits
- LPL activity. Similar to the effects of *Angptl3* ASO on AAA, *Angplt8*-deficiency or
- 426 knockdown reduced AAA formation by lowering TG concentrations and suppressing the
- 427 inflammatory response in *Apoe*-deficient mice.⁴⁰ Administration of fenofibrate also
- reduced the severity of experimental AAA in *Ldlr* and *Apoe*-deficient mice.^{41,42}
- However, fenofibrate did not significantly limit AAA growth in AAA patients in FAME-2
- 430 (Fenofibrate in the Management of Abdominal Aortic Aneurysm 2), a placebo-controlled
- 431 clinical trial.⁴³ We should note that it may take an estimated five years for a small AAA
- 432 with a diameter of 40–55 mm to reach 55 mm, the size threshold for intervention.³⁶ In
- the FAME-2 study, AAA diameters in the control group increased only about 1 mm after
- a 24-week observation period, making it hard to determine the effects of fenofibrate.
- Additionally, AAA diameters in the two groups began to diverge at the end of the
- 436 evaluation, suggesting that a long-term clinical trial with a larger sample size is needed
- to carefully assess the effects of triglyceride-lowering on AAA growth and rupture.
- 438
- 439 AAA is characterized by pathological remodeling of the aortic ECM, including elastolysis
- 440 and collagenolysis. LOX is a crucial enzyme involved in the cross-linking of collagen
- and elastin in the ECM to maintain the structural integrity of the aortic wall. Impairments

442 in LOX activity due to genetic mutations can lead to connective tissue disorders and promote aorta dissection.⁴⁴ Lox-deficient mice exhibit severe defects in vascular 443 444 development, leading to perinatal death from aortic aneurysm.³¹ β-Aminopropionitrile (BAPN) is a well-known inhibitor of LOX and has been used extensively in research to 445 accelerate AAA formation and rupture.⁴⁵ LOX is initially synthesized as a preproprotein 446 and secreted into the extracellular space, where the prolysyl oxidase is cleaved by 447 448 proteases, including BMP-1, ADAMTS-2, and ADAMTS-14. Increased TG 449 concentrations or the presence of palmitate dramatically blocked LOX maturation in 450 aortas and HASMCs. Based on RNA-seq findings, BMP-1 and ADAMTS-2 are highly 451 abundant in HASMC. PA downregulated the expression of BMP-1 and ADAMTS-2, causing decreased LOX maturation. Additionally, PA induces vascular SMC apoptosis, 452 453 promotes inflammatory responses, enhances oxidative stress, and triggers proliferation 454 and migration, contributing to the progression of vascular diseases such as atherosclerosis and hypertension.⁴⁶ In this study, we demonstrated that PA, potentially 455 originating from plasma triglycerides, may contribute to AAA development by inhibiting 456 457 LOX maturation. Lowering TG and NEFA by administration of *Angpt/3* ASO can inhibit 458 AAA development, suggesting that managing triglyceride concentrations and related metabolites through lifestyle changes and pharmacotherapy may reduce the risk of AAA 459 460 development.

461

462 Plasma TG concentrations include the content of various lipoprotein particles. Multiple genes, such as LPL, APOC3, APOC2, APOA5, and ANGPTL3, influence TG 463 464 metabolism and regulate plasma TG concentrations. Among them, APOC3 and 465 ANGPTL3 are targets for drug development because loss-of-function mutations in 466 APOC3 and ANGPTL3 are associated with improved lipid profiles and reduced 467 cardiovascular risk. Preclinical and clinical data have well documented that ApoC-III or 468 ANGPTL3 inhibitors effectively reduce severe hypertriglyceridemia. These inhibitors include antisense nucleotides (ASO),^{14,16,34} monoclonal antibodies (mAb),⁴⁷ small 469 interfering RNA (siRNA),^{48,49}, and CRISPR-cas gene editing strategies.^{50,51} Preclinical 470 471 and clinical data have demonstrated that ANGPTL3 inhibitors are highly effective for 472 treating severe hypertriglyceridemia by upregulating LPL activity and facilitating the 473 hydrolysis and clearance of TG-rich lipoproteins. As hAPOC3 transgenic mice have very 474 high APOC3 and TG concentrations, Angpt/3 ASO was administrated at 50 mg/kg/week in previous studies.¹⁶ In this study, administration of an *Angpt/3* ASO at a much lower 475 476 dosage effectively reduced AAA development in hAPOC3 transgenic mice and Apoe-477 deficient mice through reducing TG concentrations, especially TG concentrations in 478 VLDL fractions. We observed that the administration of Angpt/3 ASO mainly decreased 479 plasma TG concentrations with a limited reduction in plasma TC concentrations, further

- 480 supporting the idea that managing TG-rich lipoprotein concentrations is a potential
- 481 therapeutic strategy for treating AAA.
- 482
- In summary, the present studies, combined with recent genetic, proteomic, and
- 484 metabolomic findings, indicate that increased TG concentrations increase AAA risk.
- 485 Individuals at higher genetic risk for AAA might benefit from targeted interventions.
- 486 Understanding the association between triglyceride concentrations and AAA risk has
- 487 important clinical implications. These findings prove that ASO administration targeting
- 488 ANGPTL3 may become a therapy to reduce the risk of AAA. The present studies should
- 489 stimulate further experimental and clinical investigations of the mechanisms and
- 490 therapeutic strategies for AAA treatment via triglyceride-lowering therapies.

491 Funding

- This study was partially supported by the National Institutes of Health grants HL166203
- 493 (Y.G.), HL165688 (Y.G. and A.S.), HL109946 and HL134569 (Y.E.C.), HL151524 (L.C.),
- 494 HL153710 and HL138139 (J.Z.), HL172832 (G. Zhao), R35HL155649 (A.D.),
- 495 UL1TR001998 (A.D.), R21 NS11191 (A.S.) and the American Heart Association Merit
- 496 award 23MERIT1036341 (A.D.).
- 497

498 Disclosures

- 499 The authors have no competing interests.
- 500

501 Data availability

- 502 All genetic data used in this study were obtained from publicly available consortiums.
- 503 The RNAseq original data generated during this study will be deposited in a publicly
- 504 accessible database upon acceptance of the manuscript.

505 **References**

- Nordon, I.M., Hinchliffe, R.J., Loftus, I.M. & Thompson, M.M. Pathophysiology and epidemiology of abdominal aortic aneurysms. *Nat Rev Cardiol* 8, 92-102 (2011).
- 509 2. United Kingdom Small Aneurysm Trial, P., *et al.* Long-term outcomes of
 510 immediate repair compared with surveillance of small abdominal aortic
 511 aneurysms. *N Engl J Med* **346**, 1445-1452 (2002).
- Soden, P.A., *et al.* Outcomes for symptomatic abdominal aortic aneurysms in the
 American College of Surgeons National Surgical Quality Improvement Program. *J Vasc Surg* 64, 297-305 (2016).
- Reimerink, J.J., van der Laan, M.J., Koelemay, M.J., Balm, R. & Legemate, D.A.
 Systematic review and meta-analysis of population-based mortality from ruptured
 abdominal aortic aneurysm. *Br J Surg* **100**, 1405-1413 (2013).
- 518 5. Golledge, J., Thanigaimani, S., Powell, J.T. & Tsao, P.S. Pathogenesis and 519 management of abdominal aortic aneurysm. *Eur Heart J* **44**, 2682-2697 (2023).
- Roychowdhury, T., *et al.* Genome-wide association meta-analysis identifies risk
 loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target.
 Nat Genet 55, 1831-1842 (2023).
- 5237.Harrison, S.C., *et al.* Genetic Association of Lipids and Lipid Drug Targets With524Abdominal Aortic Aneurysm: A Meta-analysis. JAMA Cardiol 3, 26-33 (2018).
- Klarin, D., *et al.* Genetics of blood lipids among ~300,000 multi-ethnic
 participants of the Million Veteran Program. *Nat Genet* **50**, 1514-1523 (2018).
- 527 9. Norrgard, O., Angquist, K.A. & Johnson, O. Familial aortic aneurysms: serum
 528 concentrations of triglyceride, cholesterol, HDL-cholesterol and (VLDL + LDL)529 cholesterol. *Br J Surg* 72, 113-116 (1985).
- 53010.Watt, H.C., *et al.* Serum triglyceride: a possible risk factor for ruptured abdominal531aortic aneurysm. *Int J Epidemiol* **27**, 949-952 (1998).
- 532 11. Subramanian, S. Hypertriglyceridemia: Pathophysiology, Role of Genetics,
 533 Consequences, and Treatment. in *Endotext* (eds. Feingold, K.R., *et al.*) (South
 534 Dartmouth (MA), 2000).
- 535 12. Pennacchio, L.A., *et al.* An apolipoprotein influencing triglycerides in humans and 536 mice revealed by comparative sequencing. *Science* **294**, 169-173 (2001).
- 537 13. Breckenridge, W.C., Little, J.A., Steiner, G., Chow, A. & Poapst, M.
 538 Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. *N Engl J*539 *Med* 298, 1265-1273 (1978).
- 540 14. Witztum, J.L., *et al.* Volanesorsen and Triglyceride Levels in Familial 541 Chylomicronemia Syndrome. *N Engl J Med* **381**, 531-542 (2019).

542	15.	Bergmark, B.A., et al. Olezarsen for Hypertriglyceridemia in Patients at High
543		Cardiovascular Risk. <i>N Engl J Med</i> 390 , 1770-1780 (2024).
544	16.	Graham, M.J., et al. Cardiovascular and Metabolic Effects of ANGPTL3
545		Antisense Oligonucleotides. N Engl J Med 377 , 222-232 (2017).
546	17.	Rosenson, R.S., et al. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for
547		Mixed Hyperlipidemia. <i>N Engl J Med</i> (2024).
548	18.	Burgess, S., et al. Using genetic association data to guide drug discovery and
549		development: Review of methods and applications. <i>Am J Hum Genet</i> 110 , 195-
550		214 (2023).
551	19.	Gaziano, L., et al. Actionable druggable genome-wide Mendelian randomization
552		identifies repurposing opportunities for COVID-19. <i>Nat Med</i> 27 , 668-676 (2021).
553	20.	Karjalainen, M.K., et al. Genome-wide characterization of circulating metabolic
554		biomarkers. <i>Nature</i> 628 , 130-138 (2024).
555	21.	Ibrahim, M., Thanigaimani, S., Singh, T.P., Morris, D. & Golledge, J. Systematic
556		review and Meta-Analysis of Mendelian randomisation analyses of Abdominal
557		aortic aneurysms. Int J Cardiol Heart Vasc 35 , 100836 (2021).
558	22.	Raffort, J., et al. Diabetes and aortic aneurysm: current state of the art.
559		Cardiovasc Res 114 , 1702-1713 (2018).
560	23.	Daugherty, A. & Cassis, L. Chronic angiotensin II infusion promotes
561		atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci 892,
562		108-118 (1999).
563	24.	Daugherty, A., Manning, M.W. & Cassis, L.A. Angiotensin II promotes
564		atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. <i>J Clin</i>
565		<i>Invest</i> 105 , 1605-1612 (2000).
566	25.	Lu, H., et al. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function
567		Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in
568		C57BL/6 Mice-Brief Report. Arterioscler Thromb Vasc Biol 36, 1753-1757 (2016).
569	26.	Sawada, H., Lu, H.S., Cassis, L.A. & Daugherty, A. Twenty Years of Studying
570		AngII (Angiotensin II)-Induced Abdominal Aortic Pathologies in Mice: Continuing
571		Questions and Challenges to Provide Insight Into the Human Disease.
572		Arterioscler Thromb Vasc Biol 42 , 277-288 (2022).
573	27.	Mulorz, J., et al. Hyperlipidemia does not affect development of elastase-induced
574		abdominal aortic aneurysm in mice. Atherosclerosis 311 , 73-83 (2020).
575	28.	Golledge, J. Abdominal aortic aneurysm: update on pathogenesis and medical
576		treatments. Nat Rev Cardiol 16, 225-242 (2019).
577	29.	Carta, G., Murru, E., Banni, S. & Manca, C. Palmitic Acid: Physiological Role,
578		Metabolism and Nutritional Implications. <i>Front Physiol</i> 8 , 902 (2017).
579	30.	Staiculescu, M.C., Kim, J., Mecham, R.P. & Wagenseil, J.E. Mechanical behavior
580		and matrisome gene expression in the aneurysm-prone thoracic aorta of

581		newborn lysyl oxidase knockout mice. <i>Am J Physiol Heart Circ Physiol</i> 313 ,
582	21	\Box 440- \Box 450 (2017).
503	51.	anountier and dispersion in humans. Proc Natl Acad Sci U.S.A. 442 , 9750, 9764
584		(2016)
585	22	(2010). Franklin MK, at al hata Aminantanianitrila Induasa Distinct Dathalagias in the
586	32.	According and Descending Theresis Aertic Designs of Mice. Atteriopoler Thremb
587		Vasc Biol 44, 1555-1569 (2024).
589	33.	Equchi, K., et al. Saturated fatty acid and TLR signaling link beta cell dysfunction
590	•••	and islet inflammation. <i>Cell Metab</i> 15 , 518-533 (2012).
591	34.	Bergmark, B.A., et al. Effect of Vupanorsen on Non-High-Density Lipoprotein
592		Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol:
593		TRANSLATE-TIMI 70. Circulation 145, 1377-1386 (2022).
594	35.	Plump, A.S., et al. Severe hypercholesterolemia and atherosclerosis in
595		apolipoprotein E-deficient mice created by homologous recombination in ES
596		cells. <i>Cell</i> 71 , 343-353 (1992).
597	36.	Ulug, P., Powell, J.T., Martinez, M.A., Ballard, D.J. & Filardo, G. Surgery for small
598		asymptomatic abdominal aortic aneurysms. Cochrane Database Syst Rev 7,
599		CD001835 (2020).
600	37.	Liu, J., et al. Associations of ApoAI and ApoB-containing lipoproteins with AngII-
601		induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 35,
602		1826-1834 (2015).
603	38.	Ishibashi, S., Herz, J., Maeda, N., Goldstein, J.L. & Brown, M.S. The two-
604		receptor model of lipoprotein clearance: tests of the hypothesis in "knockout"
605		mice lacking the low density lipoprotein receptor, apolipoprotein E, or both
606		proteins. <i>Proc Natl Acad Sci U S A</i> 91 , 4431-4435 (1994).
607	39.	Ikezoe, T., et al. No Effect of Hypercholesterolemia on Elastase-Induced
608		Experimental Abdominal Aortic Aneurysm Progression. <i>Biomolecules</i> 11 (2021).
609	40.	Yu, H., et al. ANGPTL8 deletion attenuates abdominal aortic aneurysm formation
610		in ApoE-/- mice. <i>Clin Sci (Lond)</i> 137 , 979-993 (2023).
611	41.	Krishna, S.M., et al. Fenofibrate increases high-density lipoprotein and
612		sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm
613		progression in a mouse model. Am J Pathol 181 , 706-718 (2012).
614	42.	Golledge, J., et al. Peroxisome proliferator-activated receptor ligands reduce
615		aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 210 , 51-56
616		(2010).
617	43.	Pinchbeck, J.L., et al. Randomized Placebo-Controlled Trial Assessing the Effect
618		of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic

- 619 Aneurysm: Outcomes From the FAME -2 Trial. *J Am Heart Assoc* **7**, e009866 620 (2018).
- 44. Guo, D.C., *et al.* LOX Mutations Predispose to Thoracic Aortic Aneurysms and
 Dissections. *Circ Res* **118**, 928-934 (2016).
- 45. Kanematsu, Y.*, et al.* Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. *Hypertension* **55**, 1267-1274 (2010).
- 46. Hu, Y., Fan, Y., Zhang, C. & Wang, C. Palmitic acid inhibits vascular smooth
 muscle cell switch to synthetic phenotype via upregulation of miR-22 expression. *Aging (Albany NY)* 14, 8046-8060 (2022).
- 628 47. Gaudet, D.*, et al.* Evinacumab in homozygous familial hypercholesterolaemia: 629 long-term safety and efficacy. *Eur Heart J* **45**, 2422-2434 (2024).
- 48. Watts, G.F., *et al.* RNA interference targeting ANGPTL3 for triglyceride and
 cholesterol lowering: phase 1 basket trial cohorts. *Nat Med* 29, 2216-2223
 (2023).
- Gaudet, D., *et al.* RNA Interference Therapy Targeting Apolipoprotein C-III in
 Hypertriglyceridemia. *NEJM Evid* 2, EVIDoa2200325 (2023).
- 50. Zha, Y., *et al.* CRISPR/Cas9-mediated knockout of APOC3 stabilizes plasma
- 636 lipids and inhibits atherosclerosis in rabbits. *Lipids Health Dis* **20**, 180 (2021).
- 51. Zuo, Y., *et al.* Liver-specific in vivo base editing of Angptl3 via AAV delivery
 efficiently lowers blood lipid levels in mice. *Cell Biosci* 13, 109 (2023).

639

640 Figures

Fig. 1: Mendelian Randomization identifies circulating proteins and metabolites causally related to AAA risk.

A, Outline of the analyses performed. Two-sample Mendelian Randomization (MR) 643 644 analyses were applied to determine the causal effects of circulating proteins, and 645 nuclear magnetic resonance (NMR) measured circulating metabolites on the risk of abdominal aortic aneurysm (AAA) using multiple data sources. **B**, Forest plot displaying 646 647 the causal effects of 41 proteins identified through MR-Wald ratio analysis after Bonferroni correction. C, Classifications of NMR metabolites and the relative lipid 648 649 compositions of the 14 lipoprotein subclasses (left). All 14 lipoprotein subclass particles 650 are illustrated using the same size scale, with diameters based on mean values from 651 5.651 participants in the Northern Finland Birth Cohort 1966 (NFBC66). Note that the 652 size of the LDL and HDL particles in the figure is multiplied by 1.5 and 2.0, respectively. 653 The right side features a circular histplot of the MR results for 141 metabolites. Each 654 bar's height represents the absolute effect size, while the color indicates the direction 655 and P-value as determined by the MR inverse-variance weighted (IVW) method.

656

Fig. 2: Impaired LPL activity accelerates AAA development and aortic rupture.

658 **A**, Design of the AAA study in *LpI*-deficient mice. Inducible global *LpI*-deficient mice 659 were generated by crossing Lpl floxed (Lpf^{t/t}) mice with β -actin driven tamoxifen-660 inducible MerCreMer transgenic mice. Low cholesterol, Western diet feeding was 661 initiated 2 weeks after the start of tamoxifen treatment. **B**, Aortic rupture incidence curve 662 during 4 weeks of AnglI infusion. **C**, Aortic aneurysm incidence in *Lpl^{f/f}* (n=11) and *iLpl^{-/-}* 663 (n=10) mice. **D**, Design of the AAA study in Apoa5-deficient mice. Mice were fed a 664 standard rodent laboratory diet. After 4-week of AnglI infusion, aortas from surviving 665 mice were harvested. E, Representative aorta of male WT (n = 14) and Apoa5-deficient 666 (n = 15) mice after 4 weeks of AnglI infusion. Plasma samples were collected on day 28 667 and subjected individually to analytical chemistry to measure triglycerides (TG) and total 668 cholesterol (TC). F-J, The TG (F), TC (G), maximal aortic diameter (H), AAA incidence 669 (I), and systolic blood pressure (J) in male mice. K-O, TG (K), TC (L), maximal aortic 670 diameter (**M**), AAA incidence (**N**), and systolic blood pressure (**O**) in female WT (n = 10) 671 and Apoa5-deficient (n = 8) mice in AnglI-induced AAA study. Data are presented as 672 circles and Mean ± SEM (F-H, J -M, O). Statistical analyses were conducted as follows: 673 Chi-Squared test for C, I, N; Mann-Whitney U test for F, M; Student's t-test for G, H, K, 674 L; Kruskal-Wallis test followed by Dunn's post hoc analysis for J; One-way ANOVA followed by Sidak post hoc analysis for **O**. SBP, systolic blood pressure. 675

Fig. 3: Dramatically increased TG concentrations accelerate AAA development and rupture in hAPOC3 Tg mice.

678 A, Design of the AAA study in human APOC3 transgenic (hAPOC3 Tg) mice. Twelve- to 16-week-old hAPOC3 Tg mice (n of male = 15; n of female = 24) or WT littermates (n of 679 680 male = 17, n of female = 21) were infused with AngII (1,000 ng/kg/min) for 4 weeks to 681 induce AAA. Systolic blood pressures were measured before and after AnglI infusion. 682 The mice were fed a standard rodent laboratory diet. After 4 weeks, aortas from 683 surviving mice were harvested. Plasma samples were collected on day 28 and 684 subjected individually to analytical chemistry. **B-D**, plasma triglycerides (TG) (**B**), total 685 cholesterol (TC) (C), and non-esterified fatty acids (D) in male mice. Representative 686 aortas of male WT and hAPOC3 Tg mice after 4 weeks of AnglI infusion (E). Maximal 687 aortic diameter (F), AAA incidence (G), dissection rate (H), and systolic blood pressure 688 (I) in male mice. J-Q, The TG (J), TC (K), non-esterified fatty acids (L), maximal aortic 689 diameter (**M**), AAA incidence (**N**), and dissection rate (**O**) in female WT and hAPOC3 Tg 690 mice after 4 weeks of AnglI infusion. Data are presented as circles and Mean ± SEM (B-691 **D**, **F**, **I-M**). Statistical analyses were conducted as follows: Mann-Whitney U test for **B**, 692 D, F, J, K; Student's t-test for C, L, M; Chi-Squared test for G, H, N, O; One-way 693 ANOVA followed by Sidak post hoc analysis for I. Scale bars: 1 mm in E. SBP, systolic 694 blood pressure; NEFA, non-esterified fatty acids.

695

Fig. 4: Palmitic acid inhibits LOX maturation in HASMCs and aortas.

697 A-F, Human aortic smooth muscle cells (HASMCs) were starved in OptiMEM-reduced 698 serum medium for 24 hours, followed by incubation with palmitic acid (250 µM; PA) or 699 vehicle (BSA) for another 24 hours. Total RNA was extracted for RNA sequencing or 700 gRT-PCR. A, Reactome pathway enrichment analysis of down-regulated genes in the 701 PA group. **B**, Top 5 downregulated Reactome pathways identified from Gene Set 702 Enrichment Analysis (GSEA). C, Heatmap of gene expression levels in the collagen chain trimerization pathway. **D**, Heatmap of gene expression levels involved in elastic 703 704 fiber formation and maturation. gRT-PCR analysis of LOX (E) and BMP1, ADAMTS2, 705 and ADAMTS14 (F) (data from 4 independent experiments). G, I, HASMCs were 706 starved in OptiMEM for 24 hours, then incubated with PA (250 µM) or vehicle along with 707 TGF- β (10 ng/ml) or vehicle for another 24 hours. Total proteins were extracted for 708 Western blot analysis. G. Representative Western blot image of mature LOX and 709 premature form of LOX. I, Quantification analysis of mature LOX protein abundance 710 (data from 5 independent experiments). H, HASMCs were transfected with adenovirus 711 LacZ or LOX (30 MOI) for 2 hours in a growth medium, then starved in OptiMEM for 712 another 22 hours. Cells were incubated with PA (250 µM) or vehicle for an additional 24

- 713 hours. Total proteins were then extracted for Western blot analysis of mature and
- premature LOX. J, Eight-week-old male C57BL/6J mice were given saline, vehicle, or
- ethyl palmitate (600 mg/kg) for 5 consecutive days via intraperitoneal injection. On day
- 6, mice were euthanized, suprarenal abdominal aortas were isolated, and total protein
- 717 was extracted and analyzed by Western blot to detect mature LOX abundance in
- suprarenal abdominal aortas, with corresponding quantifications (n = 5/group). K,
- Twelve- to 16-week-old hAPOC3 Tg mice and littermate control mice were infused with
- saline or AngII (1,000 ng/kg/min) for 7 days. On day 8, mice were euthanized,
- suprarenal abdominal aortas were isolated, and total protein was extracted and
- analyzed by Western blot to detect mature LOX expression in suprarenal abdominal
- aortas, with corresponding quantifications (n = 3 or 4/genotyping/treatment). Data are
- presented as dots and Mean ± SEM (**E**, **F**, **I-K**). Statistical analyses were conducted as
- follows: Student's t-test for **E**, **F**; Mann-Whitney U test followed by Bonferroni correction
- for I; One-way ANOVA followed by Sidak post hoc analysis for J, K.
- 727

Fig. 5: Administration of Angpt/3 ASO prevents AAA formation in hAPOC3 Tg mice.

730 A, Design of the Angpt/3 ASO study in human APOC3 Tg mice. Twelve- to 16-week-old 731 male hAPOC3 Tg mice were given one injection of Angpt/3 ASO (10 mg/kg) or 732 scrambled ASO by subcutaneous administration. After 3 days, mice were infused with 733 Angll (1,000 ng/kg/min) for 25 days. Three more injections (3 mg/kg) were conducted 734 on days 7, 14, and 21. A wild-type group was included, receiving injections of scramble 735 ASO. At the end of the study, aortas, livers, and plasma were harvested. B, Relative 736 abundance of Angptl3 mRNA in livers of the three groups. C-D, Plasma ANGPTL3 737 protein concentrations (C) and non-esterified fatty acids (D) at the endpoint. E to F, 738 Plasma triglycerides (TG) (E) and total cholesterol (TC) (F) concentrations on days 0, 3, 739 and 28. **G**, Representative aortic trees from the 3 groups. **H**, Representative H&E staining (left) and Verhoeff-Van Gieson (VVG) staining (right) of suprarenal abdominal 740 741 aorta sections. I-L, Quantifications of AAA incidence (I), maximal aorta diameter (J), 742 elastic fiber degradation score (K), and dissection rate (L) among the 3 groups. M. 743 Relative abundance of Apoc3 in the liver. N. Plasma mouse-specific APOC3 744 concentrations were measured by ELISA at the endpoint. O. Relative liver abundance of 745 human APOC3. P. Plasma human APOC3 concentrations were determined by ELISA at 746 the endpoint. **Q**, Body weight comparisons among the 3 groups before and at the end of 747 the study. R, Systolic blood pressure comparisons among the 3 groups before and at 748 the end of the study. Data are presented as circles/dots and Mean \pm SEM or Mean only. 749 Statistical analyses were conducted as follows: One-way ANOVA followed by Sidak post

hoc analysis for **B**, **C**, **D**, **E**, day 3 of **F**, **M**, **N**, **R**; Kruskal-Wallis test followed by Dunn's

post hoc analysis for day 0 and 28 of **F**, **J**, **K**, **O**, **P**, **Q**; Chi-Squared test for I, L. Scale

bars: 1 mm in **G**, 50 μm in **H**. SBP, systolic blood pressure; NEFA, non-esterified fatty

acids; #, P < 0.005 of the comparison of Ctr and WT group. *, P < 0.005 of the

comparison of Ctr and ASO group.

755

Fig. 6: Administration of Angpt/3 ASO prevents AAA formation in Apoe-deficient mice.

758 **A**, Design of the *AngptI3* ASO study in male *Apoe*-deficient mice. Ten-week-old male 759 Apoe-deficient mice were given a subcutaneous injection of Angpt/3 ASO (10 mg/kg; n = 760 13) or scrambled ASO (n = 12). After 3 days, mice were infused with AngII (1,000 761 ng/kg/min) for 25 days. Three more injections were administered on days 7, 14, and 21. 762 At the end of the study, aortas, livers, and plasma were harvested. **B**, Relative 763 abundance of Angpt/3 mRNA in the liver. **C-D**, Plasma ANGPTL3 protein concentrations 764 (C), and non-esterified fatty acids (D) at the endpoint. E, Plasma triglycerides (TG) 765 levels on days 0, 3, and 28. F, Plasma total cholesterol (TC) concentrations on days 3 766 and 28. G, Systolic blood pressure before and after AnglI infusion. H, Body weight 767 changes. TG (I) and cholesterol (J) concentrations of size exclusion chromatography 768 fractionated plasma from animals (n = 4 in the control group, n = 4 in the Angpt/3 ASO 769 group) determined by enzymatic assays. Fractions 8 to 11 contained VLDL, fractions 12 770 to 17 contained IDL and LDL, and fractions 22 to 25 contained HDL. K, Representative 771 aortic images from the 2 groups. N-O, Quantification of AAA incidence (N) and maximal 772 aortic diameter (O). P, Relative liver mRNA abundance of genes related to VLDL 773 production (Apob, Mttp, Srebp1c, Scd, Fasn), TG lipolysis (Apoc2, Apoc3, Apoa5, Lpl), 774 and TC regulation (Pcsk9, Ldlr, Lrp1). Data are presented as circles/dots and/or Mean ± 775 SEM. Statistical analyses were conducted as follows: Student's t-test for **B**, **C**, day 0 776 and 28 of E, day 28 of F; Mann-Whitney U test for D, day 3 of E and F, O; One-way 777 ANOVA followed by Sidak post hoc analysis for G: Chi-Squared test for N: Student's t-778 test or Mann-Whitney U test for **P**. Scale bars: 1 mm in **K**. SBP, systolic blood pressure;

779 NEFA, non-esterified fatty acids.











